New combo may help more lung cancer patients get Life-Extending radiation
NCT ID NCT04765709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung tumors enough to allow patients to then receive radiation therapy. The trial was stopped early after enrolling only 10 people, so results are limited. The goal was to help more patients become eligible for a treatment that can control the disease longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Gustave Roussy Institute
Paris, France
-
Vall d'Hebron Barcelona Hospital
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to keep lung cancer at bay
- Step counts may predict trouble during lung cancer therapy
- New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
- New drug cocktail aims to shrink inoperable lung tumors enough for surgery
- New combo therapy aims to stop lung cancer from returning
- Blood test guides new attack on lung cancer return